A prior finding of robust cortical glutathione (GSH) deficits in patients with chronic fatigue syndrome (CFS) and major depressive disorder (MDD) provided a compelling rationale for this pilot study that aimed to assess whether 4 weeks of daily supplements of 1800mg of the GSH synthetic precursor N-acetylcysteine (NAC) would normalize brain GSH in CFS patients, as measured in vivo with J-edited MRS. The study’s main finding was that NAC supplementation significantly increased cortical GSH levels in CFS patients compared to controls, while levels of the antioxidant remained statistically unchanged in controls despite a slight numerical increase.
This abstract and the presentation materials are available to members only; a login is required.